C. Wilke

462 total citations
11 papers, 327 citations indexed

About

C. Wilke is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, C. Wilke has authored 11 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in C. Wilke's work include Advanced Breast Cancer Therapies (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and HER2/EGFR in Cancer Research (4 papers). C. Wilke is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and HER2/EGFR in Cancer Research (4 papers). C. Wilke collaborates with scholars based in France, Switzerland and United States. C. Wilke's co-authors include J. Bonneterre, Ashish Bakshi, Jean-Marc Ferrero, Martine Piccart, Igor Bondarenko, Ahmad Awada, Mario Campone, Pierfranco Conté, Elżbieta Nowara and Fabrice André and has published in prestigious journals such as Cancer Research and Annals of Oncology.

In The Last Decade

C. Wilke

11 papers receiving 326 citations

Peers

Countries citing papers authored by C. Wilke

Since Specialization

Citations

This map shows the geographic impact of C. Wilke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Wilke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Wilke more than expected).

Fields of papers citing papers by C. Wilke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Wilke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Wilke. The network helps show where C. Wilke may publish in the future.

Co-authorship network of co-authors of C. Wilke

This figure shows the co-authorship network connecting the top 25 collaborators of C. Wilke. A scholar is included among the top collaborators of C. Wilke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Wilke. C. Wilke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer 2020 ·Annals of Oncology ·Hope S. Rugo, Fabrice André, Toshinari Yamashita, (unknown), I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, Pierfranco Conté, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, (unknown), Sibylle Loibl	113
2	Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial 2019 ·Annals of Oncology ·Sibylle Loibl, Pierfranco Conté, Mario Campone, Ingrid A. Mayer, Yen‐Shen Lu, Neelima Denduluri, C. Wilke, Antonia Ridolfi, Fabrice André	2
3	Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial 2019 ·Cancer Research ·Dejan Juric, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, HS Rugo, Hiroji Iwata, Pierfranco Conté, IA Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masanori Takahashi, Zsuzsanna Pápai, (unknown), David Mills, C. Wilke, Dalila Sellami, Fabrice André	45
4	Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1 2019 ·Annals of Oncology ·Hope S. Rugo, Fabrice André, Takashi Yamashita, (unknown), I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, Pierfranco Conté, Mario Campone, C. Wilke, David Mills, (unknown), Michelle C. Miller, Sibylle Loibl	5
5	Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial 2018 ·Annals of Oncology ·Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, (unknown), David Mills, C. Wilke, Samit Hirawat, Dejan Juric	53
6	Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors 2017 ·Annals of Oncology ·Dalila Sellami, Bharani Dharan, C. Wilke, (unknown), Samit Hirawat	8
7	Abstract OT2-01-04: SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy 2017 ·Cancer Research ·Fabrice André, Bella Kaufman, Dejan Juric, Eva Ciruelos, Hiroji Iwata, IA Mayer, HS Rugo, Pierfranco Conté, (unknown), Gábor Rubovszky, Kenichi Inoue, Hans Tesch, Yen‐Shen Lu, L Ryvo, (unknown), David Mills, C. Wilke, Caroline Germa, Mario Campone	1
8	A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) 2016 ·Annals of Oncology ·Fabrice André, Bella Kaufman, Dejan Juric, Eva Ciruelos, Hiroji Iwata, Ingrid A. Mayer, Pierfranco Conté, Hope S. Rugo, Sibylle Loibl, Gábor Rubovszky, Hans Tesch, Kenichi Inoue, Yen‐Shen Lu, L Ryvo, (unknown), David Mills, C. Wilke, Caroline Germa, Mario Campone	2
9	A phase Ib dose-finding study of alpelisib (ALP; BYL719) and paclitaxel (PTX) in advanced solid tumors (aST) 2016 ·Annals of Oncology ·Jordi Rodón, Giuseppe Curigliano, Jean‐Pierre Delord, Wael A. Harb, (unknown), (unknown), (unknown), Lars Blumenstein, C. Wilke, J. Thaddeus Beck	1
10	A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC) 2014 ·Annals of Oncology ·Ahmad Awada, Igor Bondarenko, J. Bonneterre, Elżbieta Nowara, Jean-Marc Ferrero, Ashish Bakshi, C. Wilke, Martine Piccart	95
11	P3-17-06: Final Results of a Controlled, Randomized 3-Arm Phase II Trial of EndoTAG”-1, a Cationic Liposomal Formulation of Paclitaxel Targeting Tumor Endothelial Cells, in Advanced Triple-Negative Breast Cancer (TNBC). 2011 ·Cancer Research ·Ahmad Awada, Igor Bondarenko, (unknown), Jacques Bonneterre, Elżbieta Nowara, J-M Ferrero, (unknown), Heinz Weidenthaler, C. Wilke, M. Piccart	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact